N
CUE icon

Nuveen’s Cue Biopharma CUE Stock Holding History

Nuveen’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,878
Closed -$277K – 3353
2024
Q1 		$277K Sell
4,878
-1,507
-24% -$106K ﹤0.01% 3119
2023
Q4 		$506K Hold
6,385
– – ﹤0.01% 2996
2023
Q3 		$441K Buy
6,385
+1,507
+31% +$147K ﹤0.01% 2884
2023
Q2 		$534K Buy
+4,878
New +$573K ﹤0.01% 2902
2022
Q2 		– Sell
-3,911
Closed -$659K – 3298
2022
Q1 		$659K Buy
3,911
+1,134
+41% +$240K ﹤0.01% 2934
2021
Q4 		$868K Sell
2,777
-374
-12% -$145K ﹤0.01% 2901
2021
Q3 		$1.22M Sell
3,151
-57
-2% -$19.9K ﹤0.01% 2915
2021
Q2 		$1.12M Sell
3,208
-214
-6% -$82.9K ﹤0.01% 2967
2021
Q1 		$1.25M Sell
3,422
-1,323
-28% -$544K ﹤0.01% 2818
2020
Q4 		$1.78M Buy
4,745
+30
+0.6% +$12K ﹤0.01% 2567
2020
Q3 		$2.13M Sell
4,715
-113
-2% -$65.1K ﹤0.01% 2351
2020
Q2 		$3.55M Buy
4,828
+1,943
+67% +$1.41M ﹤0.01% 2079
2020
Q1 		$1.23M Sell
2,885
-1,474
-34% -$715K ﹤0.01% 2418
2019
Q4 		$2.08M Buy
4,359
+2,027
+87% +$637K ﹤0.01% 2405
2019
Q3 		$590K Buy
2,332
+220
+10% +$52.8K ﹤0.01% 2890
2019
Q2 		$570K Buy
+2,112
New +$525K ﹤0.01% 2963

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Nuveen's CUE Position: Q2 2024 in Review

Nuveen sold out of Cue Biopharma (CUE) in Q2 2024, closing a stake of 4,878 shares — an estimated $277K sold.

Nuveen first reported a position in CUE in Q2 2019 and held it in 16 quarters. The position peaked at $3.55M in Q2 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2024.

  • Nuveen reported no remaining Cue Biopharma position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 4,878 Cue Biopharma shares in Q2 2024, an estimated $277K.
  • Nuveen first reported a position in Cue Biopharma in Q2 2019 and held it in 16 quarters.
  • Nuveen's Cue Biopharma position peaked at $3.55M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.